Geographic Atrophy Market to Witness Upsurge in Growth During the Forecast Period 2032, Examine DelveInsight | Key Companies - Apellis, Iveric Bio, Hemera Biosciences, Gyroscope, Stealth BioTherapeutics, Roche (Genentech), Janssen, Allegro, Alkeus, Roche,

As per DelveInsight, the dynamics of the Geographic Atrophy (GA) market are anticipated to change in the coming years, owing to the launch of novel drugs and the rise in healthcare spending worldwide.

Globally, about 23+ companies are working on developing 25+ pipeline drugs in the Geographic Atrophy pipeline landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

DelveInsight's "Geographic Atrophy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Geographic Atrophy Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Geographic Atrophy market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Geographic Atrophy: An Overview
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration, also called age-related macular degeneration (AMD or ARMD), is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: "dry" and "wet". According to the "American Macular Degeneration Foundation," approximately 85-90% of the cases of macular degeneration are the "dry" (atrophic) type.

GA is a progressive, irreversible and blinding disease affecting both eyes. Nearly two-thirds of geographic atrophy cases are reported in people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.

Geographic Atrophy Market Key Facts
In the year 2021, the total prevalent case of Geographic Atrophy was 3,056,205 cases in the 7MM.
In the 7MM, the total treated cases of Geographic Atrophy were 1,304,611 cases in 2021. The US, in 2021, accounted for 652,223 cases (the highest number).
According to the research study by Friedman et al. (2004), the overall prevalence rate of geographic atrophy in the US population 40 years and older was 0.81 per 100 people.
According to Y. Sakurada (2016), the prevalence of GA was 6.6% among elderly Japanese with AMD.
As per Boyer et al. (2017), an estimated 973,000 people in the United States and approx. 5 million globally have GA in at least one eye.

Request for Sample PDF:
https://www.delveinsight.com/report-store/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Geographic Atrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Geographic Atrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Geographic Atrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Download the Sample Pages to Discover More About the Report Offerings:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Geographic Atrophy Epidemiology
The epidemiology section covers detailed insights into the historical and current Geographic Atrophy patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

Geographic Atrophy Epidemiology Segmentation
Total Prevalent Cases of Geographic Atrophy
Total Geographic Atrophy Cases by Visual Impairment
Total Diagnosed cases of Geographic Atrophy
Total Diagnosed cases of Geographic Atrophy by Age Distribution
Treated cases of Geographic Atrophy

Geographic Atrophy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Geographic Atrophy market or expected to get launched in the market during the study period. The analysis covers Geographic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Geographic Atrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Pipeline Development Activities:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Some of the key companies in the Geographic Atrophy Therapeutics Market include:
Apellis Pharmaceuticals
Iveric Bio
Hemera Biosciences
Gyroscope Therapeutics
Stealth BioTherapeutics
Roche (Genentech)
CellCure Neurosciences
Janssen Research & Development, LLC
Allegro Ophthalmics
Alkeus Pharmaceuticals
Regenerative Patch Technologies
Roche/Genentech
Ionis Pharmaceuticals/Roche
CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics)
And many more

Geographic Atrophy Therapies covered in the report include:
Zimura (avacincaptad pegol)
Pegcetacoplan (formerly known as APL-2),
HMR59/AAVCAGsCD59
Risuteganib/ALG-1001/Luminate
ALK-001
Elamipretide
GT005
CPCB-RPE1
RO7171009/RG6147
IONIS-FB-LRx
OpRegen
Palucorcel/CNTO 2476
And many others

Learn More About the Emerging Therapies & Key Companies in the Geographic Atrophy Therapeutics Market:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Geographic Atrophy Competitive Intelligence Analysis
4. Geographic Atrophy Market Overview at a Glance
5. Geographic Atrophy Disease Background and Overview
6. Geographic Atrophy Patient Journey
7. Geographic Atrophy Epidemiology and Patient Population
8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Geographic Atrophy Unmet Needs
10. Key Endpoints of Geographic Atrophy Treatment
11. Geographic Atrophy Marketed Products
12. Geographic Atrophy Emerging Therapies
13. Geographic Atrophy Seven Major Market Analysis
14. Attribute Analysis
15. Geographic Atrophy Market Outlook (7 major markets)
16. Geographic Atrophy Access and Reimbursement Overview
17. KOL Views on the Geographic Atrophy Market.
18. Geographic Atrophy Market Drivers
19. Geographic Atrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Geographic Atrophy Market report here:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Download the sample report:
https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park,
Sector-21, Dwarka,
New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.